Evidence map›Paper›PMID 35233703›Full record

ReviewReviews in endocrine & metabolic disorders2022

The role of vitamin D in cardiovascular disease and COVID-19.

Elissa Driggin, Mahesh V Madhavan, Aakriti Gupta

Open access · bronzeAbstract readReview
In one paragraph

Review in Reviews in endocrine & metabolic disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Vitamin D Status and Cardiovascular Disease in College Athletes After SARS-CoV-2 Infection.Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine · 2024
    Article
  4. Alterations of whole body glucose metabolism in a feline SARS-CoV-2 infection model.American journal of physiology. Regulatory, integrative and comparative physiology · 2024
    Article
  5. Article
  6. Article
  7. Observational
  8. Severe COVID-19: Drugs and Clinical Trials.Journal of clinical medicine · 2023
    Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Elissa DrigginNew York-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Mahesh V MadhavanNew York-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA.
Aakriti GuptaNew York-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, NY, USA. ag3786@cumc.columbia.edu.ORCID 0000-0001-9103-9872
NewYork–Presbyterian Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with pre-existing cardiovascular disease (CVD) are at high risk for adverse outcomes with coronavirus disease 2019 (COVID-19). Further, COVID-19 infection is associated with numerous cardiovascular (CV) complications including arrhythmia, myocardial injury, cardiomyopathy, and thrombotic events. Increased susceptibility to COVID-19 and CV complications related to COVID-19 may be in part related to immune dysregulation and inflammation associated with CV disease which is exacerbated with viral infection. Vitamin D plays a major role in immune function and exerts anti-inflammatory effects, which may prove important in the context of CVD and COVID-19. To date, studies have shown minimal benefit for vitamin D supplementation in patients with COVID-19, though there are no studies specific to patients with CVD and related complications. Further, given that vitamin D has important protective effects on the CV system, including augmentation of myocardial contractility and anti-thrombotic effects, it is unknown if supplementation with vitamin D can mitigate CVD complications associated with COVID-19.

Indexed as

Cardiovascular DiseasesCOVID-19COVID-19 Drug TreatmentVitamin D DeficiencyHumansVitamin DVitaminsVitamin DVitaminsCoagulopathyCoronavirusCOVID-19Vitamin D

Identifiers

PMID35233703
PMCPMC8888268
OpenAlexW4214922725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.